Evidence map›Paper›PMID 24489700›Full record

ArticlePloS one2014

Structural insights into complexes of glucose-regulated Protein94 (Grp94) with human immunoglobulin G. relevance for Grp94-IgG complexes that form in vivo in pathological conditions.

Andrea Pagetta, Elisa Tramentozzi, Elena Tibaldi, Laura Cendron, Giuseppe Zanotti, Anna Maria Brunati, Maurizio Vitadello, Luisa Gorza, Paola Finotti

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. The HSP Immune Network in Cancer.Frontiers in immunology · 2021
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Andrea PagettaDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.
Elisa TramentozziDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.
Elena TibaldiDepartment of Molecular Medicine, University of Padova, Padova, Italy.
Laura CendronDepartment of Biomedical Sciences, University of Padova, Padova, Italy.
Giuseppe ZanottiDepartment of Biomedical Sciences, University of Padova, Padova, Italy.
Anna Maria BrunatiDepartment of Molecular Medicine, University of Padova, Padova, Italy.
Maurizio VitadelloCentro Nazionale delle Ricerche, CNR - Institute of Neurosciences, Padova Section, Padova, Italy.
Luisa GorzaDepartment of Biomedical Sciences, University of Padova, Padova, Italy.
Paola FinottiDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.
University of Padua · ITNeuroscience Institute · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While the mechanism by which Grp94 displays its chaperone function with client peptides in the cell has been elucidated extensively, much less is known about the nature and properties of how Grp94 can engage binding to proteins once it is exposed on the cell surface or liberated in the extra-cellular milieu, as occurs in pathological conditions. In this work, we wanted to investigate the molecular aspects and structural characteristics of complexes that Grp94 forms with human IgG, posing the attention on the influence that glycosylation of Grp94 might have on the binding capacity to IgG, and on the identification of sites involved in the binding. To this aim, we employed both native, fully glycosylated and partially glycosylated Grp94, and recombinant, non-glycosylated Grp94, as well as IgG subunits, in different experimental conditions, including the physiological setting of human plasma. Regardless of the species and type, Grp94 engages a similar, highly specific and stable binding with IgG that involves sites located in the N-terminal domain of Grp94 and the hinge region of whole IgG. Grp94 does not form stable complex with Fab, F(ab)2 or Fc. Glycosylation turns out to be an obstacle to the Grp94 binding to IgG, although this negative effect can be counteracted by ATP and spontaneously also disappears in time in a physiological setting of incubation. ATP does not affect at all the binding capacity of non-glycosylated Grp94. However, complexes that native, partially glycosylated Grp94 forms with IgG in the presence of ATP show strikingly different characteristics with respect to those formed in absence of ATP. Results have relevance for the mechanism regulating the formation of stable Grp94-IgG complexes in vivo, in the pathological conditions associated with the extra-cellular location of Grp94.

Indexed as

AnimalsGlycosylationHumansImmunoglobulin GMembrane GlycoproteinsProtein BindingProtein Structure, SecondaryRatsendoplasminImmunoglobulin GMembrane Glycoproteins

Identifiers

PMID24489700
PMCPMC3904872
OpenAlexW1997525283

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.